This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|February 27, 2020
MabPlex Launches New 2000-L Cell Culture Production Lines
Author(s)BioPharm International Editors
The expansion gives the company diversified capacity running cell production lines featuring Sartorius-brand 2000-L disposable bioreactors and now GE-brand 2000-L single-use bioreactors.
Advertisement
MabPlex International, a contract development and manufacturing organization has started operations of two cell culture production lines of GE-brand 2000-L single-use bioreactors, the company announced on Feb. 25.
In addition, the company will further expand by adding two more production lines by the end of March 2020, which will feature Thermo-Fisher Scientific-brand 2000-L disposable bioreactors for clinical production. The company already runs Sartorius brand 2000-L disposable bioreactors.
"MabPlex offers one of the few globally integrated service platforms with high production capacity, something that is unique in our industry," said Yongjian Wu, PhD, chief operating officer, MabPlex USA, in a company press release.
The company has previously introduced a variety of international mainstream brand equipment for independent production lines to carry out multiple contract manufacturing processes designed to meet the varying needs of global customers. The company’s approach significantly reduces customer cost and shortens the drug-to-market cycle, according to the press release.
Source: MabPlex USA
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5